Internal use

EUROPEAN

HEMATOLOGY





The 18<sup>th</sup> Annual

# Sickle Cell & Thalassaemia Conference

IMPROVING THE LIVES OF PEOPLE LIVING WITH SICKLE CELL DISEASE & THALASSAEMIA

## **28TH OCTOBER 2023**

Welcome To ASCAT

## 08.00 - 09.00

WELCOME BREAKFAST

## 09.00 - 11.15

**ORAL ABSTRACTS PARALLEL SESSIONS** 

## 11.15 - 11.30

#### **COMFORT BREAK**

## 11.30 – 12.30

### SESSION ONE: Chair: Lydia Pecker

It Takes a Village: Infertility Risks, Fertility Preservation, Pregnancy and Intrauterine Cure In the Haemoglobinopathies

Expecting More: Infertility Risks Associated with Disease, Treatment & Cure in the Haemoglobinopathies *(15 mins)* Clinical Trials and SCD Pregnancy: A Report from the TAPS-2 Investigators and Opportunities for Intrauterine Cure *(15 mins)* 

Session Discussion, Questions & Answers (15 mins) Lydia Pecker and Eugene Oteng-Ntim

## 12.00 - 15.00



**County Hall** 

**Belvedere** Road

London SEI 7PB

25-28

OCTOBER

EUROBLOODNET: CLOSED SESSION UNDER INVITATION\*

Exploring patients-doctors dynamics, how to build assertiveness

\*Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

This project is carried out within the framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 101085717. ERN-EuroBloodNet is partly co-funded by the European Union within the framework of the Fourth EU Health Programme. Internal use

EUROPEAN HEMATOLOGY ASSOCIATION

**County Hall** 

**Belvedere** Road

London SEI 7PB

25-28

OCTOBER





The 18<sup>th</sup> Annual

# Sickle Cell & Thalassaemia Conference

IMPROVING THE LIVES OF PEOPLE LIVING WITH SICKLE CELL DISEASE & THALASSAEMIA

## **28TH OCTOBER 2023**

Welcome To ASCAT

## 12.30 - 13.30

NETWORKING LUNCH

## 13.30 - 15.05

### SESSION TWO: Chairs: Maria Capellini and Miguel Abboud

#### Hydroxyurea Therapy and New Therapies

Are Genetic Modifiers the Answer to Different Responses to Hydroxyurea Treatment? A Pharmacogenetic Study in Sickle Cell Anemia Angolan Children *(15 mins)* Panel Discussion: Hydroxyurea: Treatment Objectives and Dosaging – High v Low & Middle Income Settings *(60 mins) Miguel Brito, Michael R Debaun and Russell Ware* 

### 15.05 - 15.30

#### **PATIENT RECAP**

With EuroBloodNet

## 15.30 - 16.00

ASCAT 2023 RECAP With Andrew Campbell and Crawford Strunk